Linscomb & Williams Inc. grew its holdings in Pfizer Inc. (NYSE:PFE) by 4.9% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 123,941 shares of the biopharmaceutical company’s stock after purchasing an additional 5,768 shares during the period. Linscomb & Williams Inc.’s holdings in Pfizer were worth $4,425,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also modified their holdings of the company. Shine Investment Advisory Services Inc. acquired a new position in Pfizer in the second quarter worth approximately $102,000. Mckinley Capital Management LLC Delaware acquired a new position in Pfizer in the second quarter worth approximately $103,000. D. Scott Neal Inc. increased its holdings in Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the last quarter. Herndon Capital Management LLC acquired a new position in Pfizer in the second quarter worth approximately $120,000. Finally, Private Vista LLC increased its holdings in Pfizer by 2,277.3% in the second quarter. Private Vista LLC now owns 199,317 shares of the biopharmaceutical company’s stock worth $133,000 after buying an additional 190,933 shares during the last quarter. Institutional investors own 69.75% of the company’s stock.
In other news, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the completion of the sale, the insider now directly owns 117,432 shares of the company’s stock, valued at $4,145,349.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Alexander R. Mackenzie sold 6,750 shares of the stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the sale, the insider now directly owns 103,458 shares of the company’s stock, valued at $3,827,946. The disclosure for this sale can be found here. Insiders sold 29,450 shares of company stock valued at $1,065,220 over the last three months. 0.06% of the stock is owned by company insiders.
Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same period in the prior year, the business earned $0.61 earnings per share. Pfizer’s revenue for the quarter was up .9% compared to the same quarter last year. equities analysts forecast that Pfizer Inc. will post 2.59 EPS for the current fiscal year.
Pfizer announced that its board has authorized a stock repurchase plan on Monday, December 18th that allows the company to repurchase $10.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company’s management believes its shares are undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be given a $0.34 dividend. This represents a $1.36 annualized dividend and a dividend yield of 3.69%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. The ex-dividend date is Thursday, February 1st. Pfizer’s dividend payout ratio is currently 78.53%.
PFE has been the topic of a number of research reports. UBS Group set a $40.00 price objective on Pfizer and gave the stock a “buy” rating in a report on Wednesday, December 6th. BMO Capital Markets restated a “buy” rating and issued a $39.00 price objective on shares of Pfizer in a report on Friday, November 10th. Vetr upgraded Pfizer from a “hold” rating to a “buy” rating and set a $38.82 price objective on the stock in a report on Thursday, November 23rd. Zacks Investment Research upgraded Pfizer from a “hold” rating to a “buy” rating and set a $40.00 price objective on the stock in a report on Tuesday, October 3rd. Finally, Jefferies Group set a $39.00 price objective on Pfizer and gave the stock a “neutral” rating in a report on Thursday, November 16th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $38.88.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
What are top analysts saying about Pfizer? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer and related companies.